Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna Shares Higher After Interim Data for Covid-19 Vaccine in Children

10/25/2021 | 11:28am EST

By Michael Dabaie

Moderna Inc. shares were up 5% to $342.35 in afternoon trading after the company said it had positive interim data from the Phase 2/3 study of its Covid-19 vaccine candidate in children age six to 11.

The interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 microgram dose level with a favorable safety profile, the company said Monday.

Moderna plans to submit the data to the Food and Drug Administration, European Medicines Agency and other global regulators in the near term.

The Moderna positive follows Pfizer recently saying it is seeking emergency use authorization for its vaccine in children.

Pfizer Inc. in early October said it and BioNTech officially submitted a request to the FDA for emergency use authorization of their Covid-19 vaccine in children ages five to 11.

Pfizer and BioNTech in late September unveiled results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children five to 11 years of age using a two-dose regimen administered 21 days apart, with a smaller dose than that used for people 12 and older.

Pfizer in September said results in children under five years of age are expected as soon as later this year.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

10-25-21 1328ET

All news about MODERNA, INC.
09:06aCovid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
07:09aFederal Contractor And Subcontractor Vaccine Mandate Temporarily Enjoined In Kentucky, ..
AQ
12/03U.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
RE
12/03U.S. CDC Says Delivered 580,893,145 Doses Of Covid-19 Vaccine As Of Dec 3
RE
12/03U.S. CDC Reports Total Novel Coronavirus Cases Of 48,767,329 As Of Yesterday
RE
12/03Vaccine makers could make Omicron-specific booster, says Fauci
RE
12/03PUMP / DUMP #13 : This week's gainers and losers
12/03UK jabs deal to 'future-proof' immunisation
AQ
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
MT
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Capitalization 124 B 124 B -
EV / Sales 2021 6,42x
EV / Sales 2022 4,93x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 306,72 $
Average target price 272,53 $
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298
ICON PUBLIC LIMITED COMPANY39.92%22 206